{
    "comments": "Angiotensin (1-7) is a naturally occurring peptide that is cleaved from angiotensin 1 or angiotensin 2 by the actions of the enzymes ACE2 and MME respectively.",
    "bioactivityComments": "",
    "clinicalUse": "A pharmaceutical formulation of angiotensin (1-7) known as a TXA127 was advanced as a therapeutic by Tarix Pharmaceuticals for the management of rare neuromuscular and connective tissue diseases. Click <a href=\"https://clinicaltrials.gov/ct2/results?cond=&term=TXA127\" target=\"_blank\">here</a> to link to <i>ClinicalTrials.gov's</i> full list of TXA127 trials. In June 2017 the EMA granted TXA127 orphan drug designation for the treatment of epidermolysis bullosa.<br><br><b>SARS-CoV-2 and COVID-19:</b> In response to the COVID-19 pandemic, trials of angiotensin (1-7) in patients with severe COVID-19 were initiated, to determine if administration of angiotensin (1-7) might prevent acute kidney injury and deterioration into multi-organ failure in these patients. The proposition is that exogenous angiotensin (1-7) would normalise the angiotensin II/ angiotensin (1-7) balance that is disrupted by SARS-CoV-2 binding to ACE2 (loss of ACE2 > elevated/excessive angiotensin II > tissue injury).",
    "mechanismOfAction": "",
    "absorptionAndDistribution": "",
    "metabolism": "",
    "elimination": "",
    "populationPharmacokinetics": "",
    "organFunctionImpairment": "",
    "immuno": "",
    "gtmp": ""
}